Ironwood Inks $1 Billion Deal to Acquire VectivBio
Ironwood Pharmaceuticals’ acquisition of VectivBio grants it the rights to apraglutide, a glucagon-like peptide being evaluated for gastrointestinal diseases.
uBriGene Expands into US Market with Acquisition of Mustang Bio's CGT Manufacturing Facility
uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.
Myeloid Therapeutics Gets $73 Million to Advance mRNA-based Pipeline
With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.
The United States and the Global BioPharma Market
Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.
How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer
Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.
Launch of Sania Therapeutics Expected to Advance Development of Novel Therapeutics for Neural Circuit Dysfunction
Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.
Gilead Sciences and Arcus Biosciences Expand Research Partnership
Gilead Sciences and Arcus Biosciences have expanded their research collaboration to include inflammatory diseases in addition to oncology.
Astellas and Sony Enter ADC Platform Collaboration
Astellas and Sony will collaborate to discover a novel ADC platform for use in oncology.
FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics
In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.
BiOneCure Therapeutics and Nanjing Leads Biolabs Partner to Develop ADCs for Solid Tumors
Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.
Amgen and Tscan Therapeutics Team Up to Identify Novel Targets in Crohn's Disease
In a deal potentially worth more than $530 million, Amgen will use TScan Therapeutics’ target discovery platform to home in on novel targets for Crohn’s disease treatment.
Sandoz and Just – Evotec Biologics Form Biosimilars Pact
The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.
Baxter Divests BioPharma Solutions Department in $4.25 Billion Deal
Private investors from Advent International and Warburg Pincus will operate the assets as an independent CDMO.
Ginkgo Bioworks and Boehringer Ingelheim Sign $405 Million Drug Discovery Deal
Boehringer Ingelheim will use Ginkgo’s metagenomic sequence database to identify potential lead molecules for diseases with high unmet patient needs.
Ramping Up Nucleic Acid Therapy Development
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
Young Pups and Leopards
The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.
Aspect Biosystems, Novo Nordisk Partner to Develop Bioprinted Tissue Therapeutics
Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.
EHA Data Leak Shows Positive J&J Cancer Treatment Findings
The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.
Indian Pharma Companies Poised for Surge?
A report from Business Standard highlighted India’s recent growth in the pharma sector.
GSK and BELLUS Health Enter Acquisition Agreement
GSK has reached an agreement to acquire late-stage biopharmaceutical company BELLUS Health.
Merck to Purchase Prometheus Biosciences for $10.8 Billion
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
Caribou Biosciences Gets FDA Granted Fast Track Designation for Allogeneic CAR-T Cell Therapy
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
Novo Nordisk and Aspect Biosystems Enter Strategic Partnership
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
Ginkgo Bioworks Acquires AAV Capsid Technology and Forms Partnership for Next-Gen CAR-T Cell Therapies
Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.
AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
FDA Regulatory Authority Under Attack
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
J&J Proposes $8.9 Billion Payment in Talc Powder Litigation
If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.
Sartorius to Acquire Polyplus in $2.6 Billion Deal
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
A New Hope for Children Living with HIV
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
Zauberkugel: Pfizer’s Seagen Acquisition
What can we take away from Pfifzer's acquisition of Seagen?
